Related Experiment Video
Updated: Dec 26, 2025
07:50
An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
Published on: June 4, 2021
3.1K
Therapeutics targeting the fibrinolytic system
Haili Lin1, Luning Xu1, Shujuan Yu2
1Department of Pharmacy, Sanming First Hospital, 365000, Sanming, Fujian, People's Republic of China.
Experimental & Molecular Medicine
|March 11, 2020
Summary
The fibrinolytic system dissolves fibrin to keep blood vessels open. Its dysregulation links to diseases like thrombosis and cancer, making it a therapeutic target.
Area of Science:
- Biochemistry
- Physiology
- Pathology
Background:
- The fibrinolytic system's primary role is fibrin dissolution for vascular patency.
- Established links exist between fibrinolysis and numerous physiological and pathological processes.
- Dysregulation of fibrinolysis is implicated in thrombosis, inflammation, cancer, and neuropathies.
Purpose of the Study:
- To review current therapeutic agents targeting the fibrinolytic system.
- To discuss novel therapeutic strategies in experimental development.
- To explore future directions for fibrinolytic system modulators.
Main Methods:
- Literature review of existing and experimental fibrinolytic agents.
- Analysis of the role of fibrinolysis in various pathological conditions.
- Synthesis of information on therapeutic and diagnostic targeting.
Main Results:
- The fibrinolytic system is crucial for maintaining vascular health.
- Fibrinolytic system dysregulation is a hallmark of several diseases.
- Current and novel agents targeting fibrinolysis show therapeutic potential.
Conclusions:
- Molecules within the fibrinolytic system represent significant therapeutic and diagnostic targets.
- Continued research into fibrinolytic system modulators is warranted.
- Targeting fibrinolysis offers promising avenues for treating diverse pathological conditions.
Related Concept Videos
01:16Clot Retraction and Fibrinolysis
8.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.1K
01:29Venous Thrombosis III: Interprofessional Care
222
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
222
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.9K
01:26Targets for Drug Action: Overview
9.8K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.8K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
970
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
970